• OPEN AN ACCOUNT
Indian Indices
Nifty
25,114.00 108.50
(0.43%)
Sensex
81,904.70 355.97
( 0.44%)
Bank Nifty
54,809.30 139.70
( 0.26%)
Nifty IT
36,110.75 107.30
( 0.30%)
Global Indices
Nasdaq
45,857.35 271.66
(-0.59%)
Dow Jones
6,605.38 -3.09
(-0.05%)
Hang Seng
44,778.02 405.52
(0.91%)
Nikkei 225
9,283.29 -14.29
(-0.15%)
Forex
USD-INR
88.28 0.18
(0.20%)
EUR-INR
103.39 0.27
(0.26%)
GBP-INR
119.55 0.32
(0.27%)
JPY-INR
0.60 0.00
(0.17%)

EQUITY - MARKET SCREENER

GHV Infra Projects Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
505504
INE809Q01012
29.5352064
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
102.82
2255.88
EPS(TTM)
Face Value()
Div & Yield %
15.22
10
0
 

Glenmark USA to launch Eribulin Mesylate Injection, mg/2 mL (0.5 mg/mL) Single-Dose Vials
Sep 02,2025

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.

Glenmark's Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc., and the company will begin distribution in September 2025.

According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection, 1 mg/2 mL (0.5 mg/mL) market achieved annual sales of approximately $66.3 million.